

Antipsychotics/Neuroleptics Treatment Selector

Charts revised November 2023.

Full information available at www.hep-druginteractions.org

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r +DSV	RDV	SOF	SOF/VEL	SOF/VEL/VOX
Amisulpride	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Aripiprazole	↔	↑	↑	↔	↑	↑	↔	↔	↔	↔
Asenapine	↔	↔	↔	↔	↓	↓	↔	↔	↔	↔
Cariprazine	↔	↑	↑	↑	↑	↑	↔	↔	↔	↔
Chlorpromazine	↔	↔	↔	↔	↑	↑	↔	↔	↔	↔
Chlorprothixene	↔	↔	↔	↔	↑ ^a	↑ ^a	↔	↔	↔	↔
Clozapine	↔	↔	↑ ^b	↔	↑	↑	↔	↔	↔	↔
Flupentixol	↔	↔	↔	↔	↑ ^c	↑ ^c	↔	↔	↔	↔
Fluphenazine	↔	↔	↔	↔	↑	↑	↔	↔	↔	↔
Haloperidol	↔	↔	↔	↔	↑	↑	↔	↔	↔	↔
Iloperidone	↔	↔	↔	↔	↑ ^d	↑ ^d	↔	↔	↔	↔
Levomepromazine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Lurasidone	↔	↑	↑	↔	↑	↑	↑	↔	↔	↔
Olanzapine	↔	↔	↔	↔	↑	↑	↔	↔	↔	↔
Paliperidone	↑	↔	↑	↑	↑	↑	↔	↔	↑	↑
Perazine	↔	↔	↔	↔	↑ ^e	↑ ^e	↔	↔	↔	↔
Pericyazine	↔	↔	↔	↔	↑ ^f	↑ ^f	↔	↔	↔	↔
Perphenazine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Pimozide	↔	↑	↑	↑	↑	↑	↔	↔	↔	↔
Pipotiazine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Prochlorperazine	↔	↔	↔	↔	↑	↑	↔	↔	↔	↔
Quetiapine	↔	↑ ^g	↑ ^g	↔	↑	↑	↔	↔	↔	↔
Risperidone	↑	↔	↑	↑	↑	↑	↔	↔	↑	↑
Sulpiride	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Tiapride	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Trifluoperazine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Ziprasidone	↔	↔	↔	↔	↑	↑	↔	↔	↔	↔
Zuclopenthixol	↔	↔	↔	↔	↑	↑	↔	↔	↔	↔

Colour Legend

█	No clinically significant interaction expected.
█	These drugs should not be coadministered.
█	Potential interaction which may require a dosage adjustment or close monitoring.
█	Potential interaction predicted to be of weak intensity.

Text Legend

↑	Potential increased exposure of the antipsychotic/neuroleptic	↑	Potential increased exposure of HCV DAA
↓	Potential decreased exposure of the antipsychotic/neuroleptic	↓	Potential decreased exposure of HCV DAA
↔	No significant effect		

Numbers refer to increased or decreased AUC as observed in drug-drug interaction studies.

- a Caution is advised, as only a modest increase in chlorprothixene may prolong QT.
- b Interaction is not deemed significant in labels, but monitoring is advised as clozapine is associated with significant toxicities.
- c A dose decrease of flupentixol should be considered.
- d A dose reduction of ~50% of Iloperidone is advised.
- e ECG monitoring is recommended; cardiac conduction abnormalities have been noted with perazine.
- f Clinical monitoring is advised, as pericyazine can prolong QT.
- g Quetiapine has a narrow therapeutic index; monitor for toxicity and consider TDM and ECG monitoring.

Abbreviations: DCV Daclatasvir ELB/GZR Elbasvir/Grazoprevir G/P Glecaprevir/Pibrentasvir LED Ledipasvir OBV/PTV/r +DSV Ombitasvir/Paritaprevir/Ritonavir +Dasabuvir
RDV Ravidasvir SOF Sofosbuvir VEL Velpatasvir VOX Voxilaprevir

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.